Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 1/2016

01-01-2016 | Review

Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis

Authors: Afsaneh Shirani, Darin T. Okuda, Olaf Stüve

Published in: Neurotherapeutics | Issue 1/2016

Login to get access

Abstract

Identifying effective therapies for the treatment of progressive forms of multiple sclerosis (MS) is a highly relevant priority and one of the greatest challenges for the global MS community. Better understanding of the mechanisms involved in progression of the disease, novel trial designs, drug repurposing strategies, and new models of collaboration may assist in identifying effective therapies. In this review, we discuss various therapies under study in phase II or III trials, including antioxidants (idebenone); tyrosine kinase inhibitors (masitinib); sphingosine receptor modulators (siponimod); monoclonal antibodies (anti-leucine-rich repeat and immunoglobulin-like domain containing neurite outgrowth inhibitor receptor-interacting protein-1, natalizumab, ocrelizumab, intrathecal rituximab); hematopoetic stem cell therapy; statins and other possible neuroprotective agents (amiloride, riluzole, fluoxetine, oxcarbazepine); lithium; phosphodiesterase inhibitors (ibudilast); hormone-based therapies (adrenocorticotrophic hormone and erythropoietin); T-cell receptor peptide vaccine (NeuroVax); autologous T-cell immunotherapy (Tcelna); MIS416 (a microparticulate immune response modifier); dopamine antagonists (domperidone); and nutritional supplements, including lipoic acid, biotin, and sunphenon epigallocatechin-3-gallate (green tea extract). Given ongoing and planned clinical trial initiatives, and the largest ever focus of the global research community on progressive MS, future prospects for developing targeted therapeutics aimed at reducing disability in progressive forms of MS appear promising.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol 2015;14:194–207.PubMedCrossRef
5.
6.
Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 2014;83:1022–1024.PubMedPubMedCentralCrossRef
7.
Thompson AJ. A much-needed focus on progression in multiple sclerosis. Lancet Neurol 2015;14:133–135.PubMedCrossRef
8.
9.
Fox RJ, Thompson A, Baker D, et al. Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler 2012;18:1534–1540.PubMedPubMedCentralCrossRef
10.
Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015;14:183–193.PubMedCrossRef
11.
12.
Davies AL, Desai RA, Bloomfield PS, et al. Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. Ann Neurol 2013;74:815–825.PubMedCrossRef
13.
Hametner S, Wimmer I, Haider L, Pfeifenbring S, Bruck W, Lassmann H. Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013;74:848–861.PubMedPubMedCentralCrossRef
14.
Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66:460–471.PubMedCrossRef
15.
Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089–1104.PubMedCrossRef
16.
Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012;135:2925–2937.PubMedCrossRef
17.
Kowarik MC, Pellkofer HL, Cepok S, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011;76:1214–1221.PubMedCrossRef
18.
Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol 2015;14:208–223.PubMedPubMedCentralCrossRef
19.
Brinar VV, Barun B. Challenges in multiple sclerosis; how to define occurence of progression. Clin Neurol Neurosurg 2013;115(Suppl. 1):S30-S34.PubMedCrossRef
20.
21.
Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17:210–218.PubMedCrossRef
22.
23.
Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606–616.PubMedCrossRef
24.
25.
Kantarci OH, Lebrun C, Siva A, et al. Primary progressive MS evolving from radiologically isolated syndrome. Ann Neurol 2015. doi:10.​1002/​ana.​24564.
26.
Okuda DT. Immunosuppressive treatments in multiple sclerosis. Handb Clin Neurol 2014;122:503–511.
27.
Anon. Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Lancet 1988;2:179–183.
28.
Anon. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group. Ann Neurol 1990;27:591–605.CrossRef
29.
Anon. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 1991;337:441–446.
30.
Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004;364:1149–1156.PubMedCrossRef
31.
Pohlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 2007;13:1107–1117.PubMedCrossRef
32.
Noseworthy JH, O'Brien P, Erickson BJ, et al. The Mayo Clinic–Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 1998;51:1342–1352.PubMedCrossRef
33.
Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:706–710.PubMedPubMedCentralCrossRef
34.
Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788–1795.PubMedCrossRef
35.
Anon. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998;352:1491–1497.CrossRef
36.
Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14–24.PubMedCrossRef
37.
Noseworthy JH, Wolinsky JS, Lublin FD, et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 2000;54:1726–1733.PubMedCrossRef
38.
Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000;54:1145–1155.PubMedCrossRef
39.
Freedman MS, Bar-Or A, Oger J, et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 2011;77:1551–1560.PubMedCrossRef
40.
Zajicek J, Ball S, Wright D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol 2013;12:857–865.PubMedPubMedCentralCrossRef
41.
Bot A, Smith D, Bot S, et al. Plasmid vaccination with insulin b chain prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 2001;167:2950–2955.PubMedCrossRef
42.
Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253:98–108.PubMedCrossRef
43.
Lublin FD, Miller D, Freedman M, et al. Oral fingolimod versus placebo in patients with primary progressive multiple sclerosis (PPMS): results of the INFORMS phase III trial. . The 67th Annual Meeting of the American Academy of Neurology, Washington, DC, April 18–25, 2015.
44.
Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002;16:183–200.PubMedCrossRef
45.
Arnason BG, Berkovich R, Catania A, Lisak RP, Zaidi M. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler 2013;19:130–136.PubMedPubMedCentralCrossRef
46.
Stafstrom CE, Arnason BG, Baram TZ, et al. Treatment of infantile spasms: emerging insights from clinical and basic science perspectives. J Child Neurol 2011;26:1411–1421.PubMedCrossRef
47.
Catania A. Neuroprotective actions of melanocortins: a therapeutic opportunity. Trends Neurosci 2008;31:353–360.PubMedCrossRef
48.
Said HM. Biotin: the forgotten vitamin. Am J Clin Nutr 2002;75:179–180.PubMed
49.
Ozand PT, Gascon GG, Al Essa M, et al. Biotin-responsive basal ganglia disease: a novel entity. Brain 1998;121:1267–1279.PubMedCrossRef
50.
Tabarki B, Al-Shafi S, Al-Shahwan S, et al. Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. Neurology 2013;80:261–267.PubMedCrossRef
51.
Sedel F, Challe G, Vignal C, Assouad R, Bellanger A, Galanaud D. A novel biotin-sensitive leukodystrophy (BSL). J Inherit Metab Dis 2011;34:S267.
52.
Sedel F, Papeix C, Bellanger A, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord 2015;4:159–169.PubMedCrossRef
53.
Tourbah A, Frenay CL, Edan G, et al. Effect of MD1003 (high doses of biotin) in progressive multiple sclerosis: results of a pivotal phase III randomized double blind placebo controlled study. The 67th Annual Meeting of the American Academy of Neurology, Wasgington, DC, April 18–25, 2015.
54.
Vergo S, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain 2011;134:571–584.PubMedCrossRef
55.
Friese MA, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med 2007;13:1483–1489.PubMedCrossRef
56.
Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem 2010;17:1942–1199.PubMedCrossRef
57.
Zhang F, Zhou H, Wilson BC, Shi JS, Hong JS, Gao HM. Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord 2012;18(Suppl. 1):S213-S217.PubMedCrossRefPubMedCentral
58.
Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res 2009;87:1037–1045.PubMedCrossRef
59.
Alme MN, Wibrand K, Dagestad G, Bramham CR. Chronic fluoxetine treatment induces brain region-specific upregulation of genes associated with BDNF-induced long-term potentiation. Neural Plast 2007;2007:26496.PubMedPubMedCentral
60.
Rudick RA, Mi S, Sandrock AW, Jr. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert Opin Biol Ther 2008;8:1561–1570.PubMedCrossRef
61.
Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 2005;8:745–751.PubMedCrossRef
62.
63.
Cadavid D, Balcer L, Galetta S, et al. Evidence of remyelination with the anti-LINGO-1 monoclonal antibody BIIB033 after acute optic neuritis. The 67th Annual Meeting of the American Academy of Neurology, Wasgington, DC, April 18–25, 2015.
64.
Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol 2008;22:12–19.PubMedCrossRef
65.
Phan H, DeReese A, Day AJ, Carvalho M. The dual role of domperidone in gastroparesis and lactation. Int J Pharm Compd 2014;18:203–207.PubMed
66.
Zhornitsky S, Yong VW, Weiss S, Metz LM. Prolactin in multiple sclerosis. Mult Scler 2013;19:15–23.PubMedCrossRef
67.
Zhornitsky S, Johnson TA, Metz LM, Weiss S, Yong VW. Prolactin in combination with interferon-beta reduces disease severity in an animal model of multiple sclerosis. J Neuroinflamm 2015;12:55.CrossRef
68.
Coyle PK. Multiple sclerosis in pregnancy. Continuum (Minneap Minn) 2014;20:42–59.
69.
Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005;6:484–494.PubMedCrossRef
70.
Bartels C, Spate K, Krampe H, Ehrenreich H. Recombinant human erythropoietin: novel strategies for neuroprotective/neuro-regenerative treatment of multiple sclerosis. Ther Adv Neurol Disord 2008;1:193–206.PubMedPubMedCentralCrossRef
71.
Li W, Maeda Y, Yuan RR, Elkabes S, Cook S, Dowling P. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol 2004;56:767–777.PubMedCrossRef
72.
Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 2007;130:2577–2588.PubMedCrossRef
73.
Radaelli M, Merlini A, Greco R, et al. Autologous bone marrow transplantation for the treatment of multiple sclerosis. Curr Neurol Neurosci Rep 2014;14:478.PubMedCrossRef
74.
Harris VK, Sadiq SA. Stem cell therapy in multiple sclerosis: a future perspective. Neurodegener Dis Manag 2015;5:167–170.PubMedCrossRef
75.
Fassas A, Anagnostopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997;20:631–638.PubMedCrossRef
76.
Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003;102:2364–2372.PubMedPubMedCentralCrossRef
77.
Fassas A, Kimiskidis VK, Sakellari I, et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 2011;76:1066–1070.PubMedCrossRef
78.
Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol 2015;72:159–169.PubMedCrossRef
79.
Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012;11:150–156.PubMedPubMedCentralCrossRef
80.
Gibson LC, Hastings SF, McPhee I, et al. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol 2006;538:39–42.PubMedCrossRef
81.
Feng J, Misu T, Fujihara K, et al. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler 2004;10:494–498.PubMedCrossRef
82.
Mizuno T, Kurotani T, Komatsu Y, et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 2004;46:404–411.PubMedCrossRef
83.
Barkhof F, Hulst HE, Drulovic J, et al. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 2010;74:1033–1040.PubMedCrossRef
84.
Jaber S, Polster BM. Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier? J Bioenerg Biomembr 2015;47:111–118.PubMedCrossRef
85.
Civenni G, Bezzi P, Trotti D, Volterra A, Racagni G. Inhibitory effect of the neuroprotective agent idebenone on arachidonic acid metabolism in astrocytes. Eur J Pharmacol 1999;370:161–167.PubMedCrossRef
86.
Fiebiger SM, Bros H, Grobosch T, et al. The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse. J Neuroimmunol 2013;262:66–71.PubMedCrossRef
87.
Salinthone S, Yadav V, Bourdette DN, Carr DW. Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS. Endocr Metab Immune Disord Drug Targets 2008;8:132–142.PubMedCrossRef
88.
Marracci GH, Jones RE, McKeon GP, Bourdette DN. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 2002;131:104–114.PubMedCrossRef
89.
Yadav V, Marracci G, Lovera J, et al. Lipoic acid in multiple sclerosis: a pilot study. Mult Scler 2005;11:159–165.PubMedCrossRef
90.
Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007;32:577–595.PubMedCrossRef
91.
De Sarno P, Axtell RC, Raman C, Roth KA, Alessi DR, Jope RS. Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J Immunol 2008;181:338–345.PubMedPubMedCentralCrossRef
92.
93.
Theoharides TC, Kempuraj D, Kourelis T, Manola A. Human mast cells stimulate activated T cells: implications for multiple sclerosis. Ann N Y Acad Sci 2008;1144:74–82.PubMedCrossRef
94.
Ribatti D. The crucial role of mast cells in blood–brain barrier alterations. Exp Cell Res 2015;338:119–125.PubMedCrossRef
95.
Vermersch P, Benrabah R, Schmidt N, et al. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol 2012;12:36.PubMedPubMedCentralCrossRef
96.
Girvan RC, Knight DA, O'Loughlin CJ, Hayman CM, Hermans IF, Webster GA. MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity. Vaccine 2011;29:545–557.PubMedCrossRef
97.
White M, Webster G, O'Sullivan D, Stone S, La Flamme AC. Targeting innate receptors with MIS416 reshapes Th responses and suppresses CNS disease in a mouse model of multiple sclerosis. PLoS One 2014;9:e87712.PubMedPubMedCentralCrossRef
98.
99.
Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 2008;7:538–547.PubMedCrossRef
100.
101.
Romme Christensen J, Ratzer R, Bornsen L, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014;82:1499–1507.PubMedCrossRef
102.
103.
Stuve O, Cravens PD, Eagar TN. DNA-based vaccines: the future of multiple sclerosis therapy? Expert Rev Neurother 2008;8:351–360.PubMedCrossRef
104.
Vandenbark AA. TCR peptide vaccination in multiple sclerosis: boosting a deficient natural regulatory network that may involve TCR-specific CD4 + CD25+ Treg cells. Curr Drug Targets Inflamm Allergy 2005;4:217–229.PubMedCrossRef
105.
Wu Y, Borde M, Heissmeyer V, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006;126:375–387.PubMedCrossRef
106.
Vandenbark AA, Culbertson NE, Bartholomew RM, et al. Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 2008;123:66–78.PubMedPubMedCentralCrossRef
107.
Raftopoulos RE, Kapoor R. Neuroprotection for acute optic neuritis – can it work? Mult Scler Relat Disord 2013;2:307–311.PubMedCrossRef
108.
Black JA, Liu S, Carrithers M, Carrithers LM, Waxman SG. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 2007;62:21–33.PubMedCrossRef
109.
Morsali D, Bechtold D, Lee W, et al. Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. Brain 2013;136:1067–1082.PubMedCrossRef
110.
Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010;9:681–688.PubMedCrossRef
111.
Beck RW, Cleary PA, Anderson MM, Jr., et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992;326:581–588.PubMedCrossRef
112.
Kolappan M, Henderson AP, Jenkins TM, et al. Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. J Neurol 2009;256:305–319.PubMedCrossRef
113.
Kapoor R, Raftopoulos R, Hickman S, et al. Phenytoin is neuroprotective in acute optic neuritis: results of a phase 2 randomized controlled trial. The 67th Annual Meeting of the American Academy of Neurology, Wasgington, DC, April 18–25, 2015.
114.
Bonnan M, Ferrari S, Bertandeau E, et al. Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials. Curr Drug Targets 2014;15:1205–1214.PubMedCrossRef
115.
Montalban X, Hemmer B, Rammohan K, et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study. Mult Scler 2015 Supplement, p780-808. 29p.
116.
van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL. Statins: mechanisms of neuroprotection. Prog Neurobiol 2009;88:64–75.PubMedCrossRef
117.
Weber MS, Youssef S, Dunn SE, et al. Statins in the treatment of central nervous system autoimmune disease. J Neuroimmunol 2006;178:140–148.PubMedCrossRef
118.
Neuhaus O, Stuve O, Zamvil SS, Hartung HP. Are statins a treatment option for multiple sclerosis? Lancet Neurol 2004;3:369–371.PubMedCrossRef
119.
Pihl-Jensen G, Tsakiri A, Frederiksen JL. Statin treatment in multiple sclerosis: a systematic review and meta-analysis. CNS Drugs 2015;29:277–291.PubMedCrossRef
120.
Stuve O, Youssef S, Steinman L, Zamvil SS. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 2003;16:393–401.PubMedCrossRef
121.
Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014;383:2213–2221.PubMedCrossRef
122.
Gonzalez-Cabrera PJ, Brown S, Studer SM, Rosen H. S1P signaling: new therapies and opportunities. F1000Prime Rep 2014;6:109.
123.
Novgorodov AS, El-Alwani M, Bielawski J, Obeid LM, Gudz TI. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J 2007;21:1503–1514.PubMedCrossRef
124.
Brana C, Frossard MJ, Pescini Gobert R, Martinier N, Boschert U, Seabrook TJ. Immunohistochemical detection of sphingosine-1-phosphate receptor 1 and 5 in human multiple sclerosis lesions. Neuropathol Appl Neurobiol 2014;40:564–578.PubMedCrossRef
125.
Soliven B, Miron V, Chun J. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators. Neurology 2011;76:S9-S14.PubMedCrossRef
126.
Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013;12:756–767.PubMedCrossRef
127.
Kappos L, Bar-Or A, Cree B, et al. Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial. The 65th Annual Meeting of the American Academy of Neurology, San Diego, CA, March 16–23, 2013.
128.
Schmitz K, Barthelmes J, Stolz L, Beyer S, Diehl O, Tegeder I. “Disease modifying nutricals” for multiple sclerosis. Pharmacol Ther 2015;148:85–113.PubMedCrossRef
129.
Caruana M, Vassallo N. Tea polyphenols in Parkinson's disease. Adv Exp Med Biol 2015;863:117–137.PubMedCrossRef
130.
Aktas O, Prozorovski T, Smorodchenko A, et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 2004;173:5794–5800.PubMedCrossRef
131.
Sun Q, Zheng Y, Zhang X, et al. Novel immunoregulatory properties of EGCG on reducing inflammation in EAE. Front Biosci 2013;18:332–342.CrossRef
132.
Hellings N, Raus J, Stinissen P. T-cell-based immunotherapy in multiple sclerosis: induction of regulatory immune networks by T-cell vaccination. Expert Rev Clin Immunol 2006;2:705–716.PubMedCrossRef
133.
134.
Fox E, Wynn D, Cohan S, Rill D, McGuire D, Markowitz C. A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design. Mult Scler 2012;18:843–852.PubMedCrossRef
135.
Robinson AP, Harp CT, Noronha A, Miller SD. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol 2014;122:173–189.PubMedPubMedCentralCrossRef
136.
Levy H, Assaf Y, Frenkel D. Characterization of brain lesions in a mouse model of progressive multiple sclerosis. Exp Neurol 2010;226:148–158.PubMedCrossRef
137.
Chataway J, Nicholas R, Todd S, et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler 2011;17:81–88.PubMedCrossRef
138.
139.
Freidlin B, Korn EL, Gray R, Martin A. Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res 2008;14:4368–4371.PubMedCrossRef
140.
Vesterinen HM, Connick P, Irvine CM, et al. Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis. PLoS One 2015;10:e0117705.PubMedPubMedCentralCrossRef
141.
142.
Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003;61:1720–1725.PubMedCrossRef
143.
Kuhle J, Plattner K, Bestwick JP, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler 2013;19:1597–1603.PubMedCrossRef
144.
Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002;125:1462–1473.PubMedCrossRef
145.
Botas A, Campbell HM, Han X, Maletic-Savatic M. Metabolomics of Neurodegenerative Diseases. Int Rev Neurobiol 2015;122:53–80.PubMedCrossRef
146.
Freidlin B, Korn EL. Biomarker-adaptive clinical trial designs. Pharmacogenomics 2010;11:1679–1682.PubMedCrossRef
Metadata
Title
Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis
Authors
Afsaneh Shirani
Darin T. Okuda
Olaf Stüve
Publication date
01-01-2016
Publisher
Springer US
Published in
Neurotherapeutics / Issue 1/2016
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-015-0409-z

Other articles of this Issue 1/2016

Neurotherapeutics 1/2016 Go to the issue

Commentary

Precision Medicine: SCN8A Encephalopathy Treated with Sodium Channel Blockers

Review

Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders

Review

Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis

Erratum

Erratum to: Remarkable Phenytoin Sensitivity in 4 Children with SCN8A-related Epilepsy: A Molecular Neuropharmacological Approach

Review

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity

Original Article

Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid